NCT07219368

A First-in-Human Single and Multiple Ascending Dose Study of MT-201

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-201 in Healthy Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Mirador Therapeutics, Inc. · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	MT-201	MT-201
DRUG	Placebo	Placebo

Timeline

• Start date: 2025-10-08
• Primary completion: 2026-11-24
• Completion: 2026-12-31
• First posted: 2025-10-21
• Last updated: 2025-11-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study